Literature DB >> 15529257

Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.

Jennifer L Harcourt1, Ruth A Karron, Ralph A Tripp.   

Abstract

Respiratory syncytial virus (RSV) is an important cause of severe lower respiratory tract illness in infants and the elderly. Presently, no safe and efficacious RSV vaccine exists; however, advances in our understanding of immunity and the pathogenesis of disease associated with RSV infection may lead to new vaccine strategies. RSV G protein contains a CX3C chemokine motif that interacts with the CX3CR1 chemokine receptor and modifies the activities of fractalkine. In the present study, we show that anti-RSV G protein antibody responses after recent RSV infection or vaccination are associated with inhibition of RSV G protein CX3C-CX3CR1 interaction and RSV G protein-mediated leukocyte chemotaxis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15529257     DOI: 10.1086/425516

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.

Authors:  Tongna Zhu; Chuanlong Zhang; Li Yu; Jingxian Chen; Huan Qiu; Weiwei Lyu; Shenghai Huang
Journal:  Virol Sin       Date:  2015-10-22       Impact factor: 4.327

3.  A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

Authors:  Shannon I Phan; Zhenhai Chen; Pei Xu; Zhuo Li; Xiudan Gao; Stephanie L Foster; Michael N Teng; Ralph A Tripp; Kaori Sakamoto; Biao He
Journal:  Vaccine       Date:  2014-04-08       Impact factor: 3.641

4.  Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Jamie N Biear; Ann R Falsey; Edward E Walsh
Journal:  Vaccine       Date:  2010-07-23       Impact factor: 3.641

5.  Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.

Authors:  Youngjoo Choi; Caleb S Mason; Les P Jones; Jackelyn Crabtree; Patricia A Jorquera; Ralph A Tripp
Journal:  Viral Immunol       Date:  2012-05-02       Impact factor: 2.257

6.  Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection.

Authors:  Crystal H Johnson; Congrong Miao; Elisabeth G Blanchard; Hayat Caidi; Gertrud U Radu; Jennifer L Harcourt; Lia M Haynes
Journal:  Comp Med       Date:  2012-02       Impact factor: 0.982

Review 7.  Unity in diversity: shared mechanism of entry among paramyxoviruses.

Authors:  Jean-Louis Palgen; Eric M Jurgens; Anne Moscona; Matteo Porotto; Laura M Palermo
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

8.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

9.  Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Authors:  Congrong Miao; Gertrud U Radu; Hayat Caidi; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

Review 10.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.